Skip to main content
. 2012 Sep 4;184(12):E675–E683. doi: 10.1503/cmaj.112102

Figure 3:

Figure 3:

Meta-analysis of the risk of bladder cancer associated with rosiglitazone use among patients with type 2 diabetes in randomized controlled trials. A value greater than 1.0 indicates an increased risk of bladder cancer with rosiglitazone use. CI = confidence interval.